Adult acne patients who can become pregnant need two negative pregnancy tests, at least 30 days apart, before starting isotretinoin. Both tests must happen in a medical setting under iPLEDGE, the FDA safety program for isotretinoin. The FDA approved iPLEDGE modifications on Feb.
9, 2026, for implementation on Aug. 9, 2026, according to the Medaptly summary of the FDA approval the Medaptly summary of the FDA approval. The changes retain pregnancy-prevention safeguards while reducing burden. Adult acne care follows the same pretreatment standard as other covered uses.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Who must complete pretreatment testing?
- What is the two-test sequence?
- Where must pretreatment tests happen?
- How do you stay inside the prescription window?
Who must complete pretreatment testing?
The FDA Absorica label applies the rules to every patient who can become pregnant prescribed isotretinoin for severe recalcitrant nodular acne. That group includes adults treated for acne.
There is no separate adult-acne pretreatment standard. Your prescriber determines whether you fit that group. If you do, you complete the full pretreatment sequence before your first dose.
What is the two-test sequence?
The FDA Contraception Counseling Guide describes a screening test when the prescribing decision is made, then a 30-day wait, then a second negative test confirmed in iPLEDGE plus comprehension questions before treatment the FDA Contraception Counseling Guide. The second test alone does not clear treatment.
Confirmation and questions must also be complete. Schedule backward from when you hope to start. The 30-day interval is mandatory, not a target range.
- negative screening test at the prescribing decision
- wait at least 30 days without starting isotretinoin
- second negative medical-setting test, iPLEDGE confirmation, and comprehension questions
Where must pretreatment tests happen?
Every test required before the first dose must occur in a medical setting, such as the prescriber office, clinic, or laboratory. Home tests do not satisfy this pretreatment step. Ask the office where each result will be documented.
The FDA removed the prior requirement for a CLIA-certified laboratory, according to the National Community Pharmacists Association the National Community Pharmacists Association report. Pretreatment tests need only a medical setting. Tests during and after treatment may use home tests when the prescriber allows them.
How do you stay inside the prescription window?
The DailyMed isotretinoin label states that patients who can become pregnant must obtain each prescription within 7 days of specimen collection, in no more than a 30-day supply after iPLEDGE authorization. Patients who cannot become pregnant have 30 days from the visit. The shorter window starts with sample collection, not the office visit date. The 19-day lockout for missing the 7-day window was eliminated, the Journal of Dermatology for NPs and PAs reports.
A repeat test can now be done immediately. If you have not yet taken a first dose, that repeat test must still be in a medical setting. Plan two office or clinic testing visits at least 30 days apart before starting isotretinoin. Confirm test location, sample date, and pickup deadline at each visit.
You Might Also Like
- Pretreatment Pregnancy Testing Under iPLEDGE in 2026: Access and Prescription-Window Questions for Adult Acne Patients
- Planned Home Pregnancy Testing Under the 2026 iPLEDGE Changes: Pregnancy Testing Questions for Adult Acne Patients
- Planned Home Pregnancy Testing Under the 2026 iPLEDGE Changes: Access and Prescription-Window Questions for Adult Acne Patients